These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 19168160)
1. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160 [TBL] [Abstract][Full Text] [Related]
2. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. Martin KE; Yu J; Campbell HE; Abarca J; White TJ J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301 [TBL] [Abstract][Full Text] [Related]
4. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Epstein S; Jeglitsch M; McCloskey E Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464 [TBL] [Abstract][Full Text] [Related]
5. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States. Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [TBL] [Abstract][Full Text] [Related]
7. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Rossini M; Viapiana O; Gatti D; Adami S Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399 [TBL] [Abstract][Full Text] [Related]
8. The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies. Alves C; Mendes D; Penedones A; Oliveira T; Donato A; Batel-Marques F Int J Clin Pharm; 2024 Apr; 46(2):357-367. PubMed ID: 38112890 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study. Lee DR; Lee J Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785 [TBL] [Abstract][Full Text] [Related]
10. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910 [TBL] [Abstract][Full Text] [Related]
11. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Gold DT; Safi W; Trinh H Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Zhou J; Ma X; Wang T; Zhai S Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103 [TBL] [Abstract][Full Text] [Related]
15. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102 [TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978 [TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Guañabens N; Monegal A; Cerdá D; Muxí Á; Gifre L; Peris P; Parés A Hepatology; 2013 Dec; 58(6):2070-8. PubMed ID: 23686738 [TBL] [Abstract][Full Text] [Related]